Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Umair Majeed

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4225-7555; OpenAlex author ID A5033898613. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 9

  1. KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. Last author DOI 10.1186/s13045-026-01863-x↗
  2. Intraperitoneal Chemotherapy Strategies in Pancreatic Ductal Adenocarcinoma: A Systematic Review of Hyperthermic Intraperitoneal Chemotherapy, Normothermic Int… Last author DOI 10.3390/cancers18020182↗
  3. Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. Co-author DOI 10.21037/jgo-2025-100↗
  4. Case Report: Gemcitabine-induced membranoproliferative glomerulonephritis with immune complexes in a patient with metastatic pancreatic cancer. Last author DOI 10.3389/fmed.2025.1666859↗
  5. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Co-author DOI 10.2147/ceg.s390655↗
  6. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Co-author DOI 10.1080/13543784.2023.2206558↗
  7. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  8. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Co-author DOI 10.3389/fonc.2021.794009↗
  9. A Rare Case of Irinotecan-induced Interstitial Pulmonary Disease and Diffuse Alveolar Hemorrhage in a Patient with Pancreatic Cancer. Co-author DOI 10.7759/cureus.5041↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hani M. Babiker · 7 shared papers, 2023–2026 · strength 1.73
  2. Mitesh J. Borad · 6 shared papers, 2021–2026 · strength 1.23
  3. Ahmed Adel Fouad Abdelhakeem · 3 shared papers, 2025–2026 · strength 0.85
  4. Nency Ganatra · 2 shared papers, 2026 · strength 0.55
  5. Tanios Bekaii‐Saab · 3 shared papers, 2021–2026 · strength 0.52
  6. Nguyen H. Tran · 2 shared papers, 2024–2025 · strength 0.49
  7. Ahmed Elhariri · 2 shared papers, 2023–2025 · strength 0.40
  8. Saivaishnavi Kamatham · 1 shared paper, 2026 · strength 0.30
  9. Daniel H. Ahn · 2 shared papers, 2021–2023 · strength 0.27
  10. Mohamad Bassam Sonbol · 2 shared papers, 2021–2023 · strength 0.27
  11. Jason Scott Starr · 2 shared papers, 2021–2023 · strength 0.27
  12. Robin John Lester Imperial · 1 shared paper, 2024 · strength 0.26
  13. Osama M. Mosalem · 1 shared paper, 2024 · strength 0.26
  14. Douaa Albelal · 1 shared paper, 2025 · strength 0.24
  15. Himil J Mahadevia · 1 shared paper, 2025 · strength 0.24
  16. Michael S. Rutenberg · 1 shared paper, 2025 · strength 0.24
  17. Jing Wang · 1 shared paper, 2023 · strength 0.22
  18. Christina Sing-Ying Wu · 1 shared paper, 2023 · strength 0.16
  19. Michael Scott Rutenberg · 1 shared paper, 2023 · strength 0.16
  20. John Andrew Stauffer · 1 shared paper, 2023 · strength 0.16
  21. Lingbin Meng · 1 shared paper, 2019 · strength 0.12
  22. Wen Wang · 1 shared paper, 2019 · strength 0.12
  23. Gehan Botrus · 1 shared paper, 2021 · strength 0.11
  24. Kabir Mody · 1 shared paper, 2021 · strength 0.11
  25. Pedro Luiz Serrano Usón · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.